These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6214446)

  • 101. Effect of amphotericin B on the incorporation of neocarzinostatin into human gastric cancerous tissues.
    Nakazawa I; Ouchi E; Ishida N; Ouchi K; Wagai K
    Tohoku J Exp Med; 1978 Jan; 124(1):97-8. PubMed ID: 147527
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Kinetic analysis of the in vitro cell-killing action of neocarzinostatin.
    Ozawa S; Inaba M
    Cancer Chemother Pharmacol; 1989; 23(5):279-82. PubMed ID: 2523252
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Long-term toxicity studies of styrene maleic anhydride in rats.
    Sethi N; Srivastava RK; Singh RK; Nath D
    Biomed Environ Sci; 1990 Dec; 3(4):452-7. PubMed ID: 2096850
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Electron spin resonance detection of free radicals in the mercaptan-activation and UV-inactivation of neocarzinostatin.
    Sheridan RP; Gupta RK
    Biochem Biophys Res Commun; 1981 Mar; 99(1):213-20. PubMed ID: 6263270
    [No Abstract]   [Full Text] [Related]  

  • 105. Isolation of a non-protein component and a protein component from neocarzinostatin (NCS) and their biological activities.
    Koide Y; Ishii F; Hasuda K; Koyama Y; Edo K; Kitamine S; Kitame F; Ishida N
    J Antibiot (Tokyo); 1980 Mar; 33(3):342-6. PubMed ID: 6445889
    [No Abstract]   [Full Text] [Related]  

  • 106. [Studies on metabolism and disposition of sizofiran (SPG), an anti-tumor polysaccharide. III. Degradation and excretion of SPG in rats].
    Tanji S; Akima K; Horiba M; Amemiya K; Aimoto T
    Yakugaku Zasshi; 1990 Nov; 110(11):869-75. PubMed ID: 2127945
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Unusual survival kinetics of neocarzinostatin-treated HeLa cells: its relation to the drug-inactivation.
    Kuroda Y; Sasaki T; Hoshino F
    J Radiat Res; 1991 Jun; 32(2):191-201. PubMed ID: 1834831
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Pharmacokinetics of neothramycin in animals and man.
    Fujita H; Ogawa K; Okada A; Kusama T; Kajii K; Suga S; Kimura K
    J Antibiot (Tokyo); 1982 Aug; 35(8):1093-100. PubMed ID: 7142009
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Tissue pharmacokinetics and inhibition of DNA synthesis in mice treated with sporamycin.
    Komiyama K; Umezawa I
    J Antibiot (Tokyo); 1978 May; 31(5):473-6. PubMed ID: 670087
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Studies on antitumor activity of prumycin. II. Studies on distribution and excretion of prumycin.
    Okubo S; Nakamura N; Morimoto M; Mineura K; Marumo H; Omura S
    J Antibiot (Tokyo); 1980 Feb; 33(2):221-5. PubMed ID: 7380732
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Metabolism of protein anticancer agents.
    Bocci V
    Pharmacol Ther; 1987; 34(1):1-49. PubMed ID: 2443936
    [No Abstract]   [Full Text] [Related]  

  • 112. Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin.
    Tsukigawa K; Liao L; Nakamura H; Fang J; Greish K; Otagiri M; Maeda H
    Cancer Sci; 2015 Mar; 106(3):270-8. PubMed ID: 25529761
    [TBL] [Abstract][Full Text] [Related]  

  • 113. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect.
    Maeda H
    Cancer Sci; 2013 Jul; 104(7):779-89. PubMed ID: 23495730
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
    Maeda H
    Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(3):53-71. PubMed ID: 22450535
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure.
    Li CJ; Miyamoto Y; Kojima Y; Maeda H
    Br J Cancer; 1993 May; 67(5):975-80. PubMed ID: 8494731
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCS.
    Masuda E; Maeda H
    Cancer Immunol Immunother; 1995 May; 40(5):329-38. PubMed ID: 7600566
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy.
    Oda T; Yamamoto H; Miki T; Maeda H
    Jpn J Cancer Res; 1989 Apr; 80(4):394-9. PubMed ID: 2526108
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin.
    Suzuki F; Pollard RB; Maeda H
    Cancer Immunol Immunother; 1989; 30(2):97-104. PubMed ID: 2480846
    [TBL] [Abstract][Full Text] [Related]  

  • 119. In vitro mode of action, pharmacokinetics, and organ specificity of poly (maleic acid-styrene)-conjugated neocarzinostatin, SMANCS.
    Takeshita J; Maeda H; Kanamaru R
    Gan; 1982 Apr; 73(2):278-84. PubMed ID: 6214446
    [TBL] [Abstract][Full Text] [Related]  

  • 120. [Tumor growth inhibitory effects of SMANCS, a poly (styrene-maleic acid) conjugated derivative of neocarzinostatin, on various tissue culture cells].
    Suzuki F; Okuno Y; Maeda Y; Maeda H
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3305-12. PubMed ID: 2961306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.